Amal Therapeutics, a Geneva based start-up Biotech Company developing and progressing therapeutic vaccines in oncology, announced today that it signed research collaboration agreement with the Oslo University Hospital (OUH)-Radiumhospitalet (Dept of Cellular Therapy). The objective of the collaboration is to validate Amal Therapeutics lead vaccine candidate using human-cells functional assay platform developed in the department.
Dr. Madiha Derouazi, CEO at Amal Therapeutics commented: Amal Therapeutics is delighted having the opportunity to collaborate with the Oslo University Hospital. I¹m convinced that the predictive human-cell assay platform developed by scientists of the Department of Cellular Therapy will be of a great help to Amal for pre-assessing its vaccines in a human in vitro environment. This work will certainly facilitate the development of safer and more efficient drugs for the patients.
Source: Amal Therapeutics